- Home
- NAGE vs DRTS Comparison
NAGE vs DRTS Comparison
Compare NAGE & DRTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NAGE | DRTS |
|---|---|---|
| Founded | 1999 | 2015 |
| Country | United States | Israel |
| Employees | N/A | 125 |
| Industry | Medicinal Chemicals and Botanical Products | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 507.6M | 546.5M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | NAGE | DRTS |
|---|---|---|
| Price | $4.81 | $6.96 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | ★ $16.00 | $8.67 |
| AVG Volume (30 Days) | ★ 1.2M | 267.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $20.75 | N/A |
| Revenue Next Year | $19.96 | $1,055.39 |
| P/E Ratio | $21.29 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.73 | $2.30 |
| 52 Week High | $14.66 | $8.60 |
Technical Indicators
Market Signals| Indicator | NAGE | DRTS |
|---|---|---|
| Relative Strength Index (RSI) | 37.09 | 47.96 |
| Support Level | $4.73 | $6.51 |
| Resistance Level | $5.32 | $7.77 |
| Average True Range (ATR) | 0.29 | 0.50 |
| MACD | 0.03 | -0.10 |
| Stochastic Oscillator | 8.53 | 28.70 |
Price Performance
Historical ComparisonAbout NAGE Niagen Bioscience Inc.
Niagen Bioscience Inc is the leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. It is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions. It is is clinically proven to increase NAD+ levels efficiently and effectively, and is the key ingredient powering our suite of Niagen brands.
About DRTS Alpha Tau Medical Ltd.
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company derives maximum revenue from Israel.